Preview Mode Links will not work in preview mode

Jul 14, 2020

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Interview with Dr Moore on the following topics:

  • Genomic testing for patients with newly diagnosed ovarian cancer (OC) (00:00)
  • Management of OC with germline BRCA mutation after surgical debulking; role of bevacizumab and PARP inhibitors (3:40)
  • Therapeutic approach for patients with homologous recombination-proficient OC (8:20)

CME information and select publications